Managing spasticity with drugs

European Journal of Physical and Rehabilitation Medicine

Volumn 46, Issue 3, 2010, Pages 401-410

  Simon, O ^a   Yelnik, A P ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Clinical protocols; Drug therapy; Muscle spasticity

Indexed keywords

BACLOFEN; BOTULINUM TOXIN A; CENTRAL MUSCLE RELAXANT; CLONIDINE; DRUG DERIVATIVE; MUSCLE RELAXANT AGENT; TIZANIDINE;

HUMAN; INTRASPINAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; REVIEW; SPASTICITY;

ADMINISTRATION, ORAL; BACLOFEN; BOTULINUM TOXINS, TYPE A; CLONIDINE; HUMANS; INJECTIONS, SPINAL; MUSCLE RELAXANTS, CENTRAL; MUSCLE SPASTICITY; NEUROMUSCULAR AGENTS;

EID: 79251609046     PISSN: 19739087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Lance JW. What is spasticity? Lancet 1990;335:606.
2. Yelnik A, Albert T, Bonan I, Laffont I. A clinical guide to assess the role of lower limb extensor overactivity in hemiplegic gait disorders. Stroke 1999;30:580-5.
3. Yelnik AP, Simon O, Bensmail D, et al. Drug treatments for spasticity. Ann Phys Rehabil Med 2009;52:746-56.
4. Poulain B, Lonchamp E, Jover E, Popoff MR, Molgo J. [Mechanisms of action of botulinum toxins and neurotoxins]. Ann Dermatol Venereol 2009;136 Suppl 4:S73-6.
5. Hambleton P, Pickett AM, Shone CC. Botulinum toxin: from menace to medicine. In: Ward AB, Barnes MP, eds. Clinical uses of botulinum toxins. Cambridge: Cambridge University Press; 2007.
6. Hambleton P, Moore AP. Botulinum neurotoxins: origin, structure, molecular actions and antibodies. Handbook of botulinum toxin treatment. Oxford: Blackwell Science; 1995.
7. Simpson DM, Gracies JM, Yablon SA, Barbano R, Brashear A. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study. J Neurol Neurosurg Psychiatry 2009;80:380-5.
8. Bakheit AM, Pittock S, Moore AP, et al. A randomized, doubleblind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol 2001;8:559-65.
9. Bakheit AM, Thilmann AF, Ward AB, Poewe W, Wissel J, Muller J et al. A randomized, double-blind, placebo-controlled, doseranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 2000;31:2402-6.
10. Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry 2000;69: 217-21.
11. Bhakta BB, O'Connor RJ, Cozens JA. Associated reactions after stroke: a randomized controlled trial of the effect of botulinum toxin type A. J Rehabil Med 2008;40:36-41.
12. Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002;347:395-400.
13. Elovic EP, Brashear A, Kaelin D, Liu J, Millis SR, Barron R et al. Repeated treatments with botulinum toxin type a produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients. Arch Phys Med Rehabil 2008;89:799-806.
14. Francisco GE, Boake C, Vaughn A. Botulinum toxin in upper limb spasticity after acquired brain injury: a randomized trial comparing dilution techniques. Am J Phys Med Rehabil 2002;81:355-63.
15. Gordon MF, Brashear A, Elovic E, Kassicieh D, Marciniak C, Liu J et al. Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke. Neurology 2004;63:1971-3.
16. Hesse S, Reiter F, Konrad M, Jahnke MT. Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, doubleblind, placebo-controlled trial. Clin Rehabil 1998;12:381-8.
17. Kong KH, Neo JJ, Chua KS. A randomized controlled study of botulinum toxin A in the treatment of hemiplegic shoulder pain associated with spasticity. Clin Rehabil 2007;21:28-35.
18. Lim JY, Koh JH, Paik NJ. Intramuscular botulinum toxin-A reduces hemiplegic shoulder pain: a randomized, double-blind, comparative study versus intraarticular triamcinolone acetonide. Stroke 2008;39:126-31.
19. Marco E, Duarte E, Vila J, Tejero M, Guillen A, Boza R et al. Is botulinum toxin type A effective in the treatment of spastic shoulder pain in patients after stroke? A double-blind randomized clinical trial. J Rehabil Med 2007;39:440-7.
20. Rousseaux M, Kozlowski O, Froger J. Efficacy of botulinum toxin A in upper limb function of hemiplegic patients. J Neurol 2002;249:76-84.
21. Simpson DM, Alexander DN, O'Brien CF, Tagliati M, Aswad AS, Leon JM et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebocontrolled trial. Neurology 1996;46:1306-10.
22. Smith SJ, Ellis E, White S, Moore AP. A double-blind placebocontrolled study of botulinum toxin in upper limb spasticity after stroke or head injury. Clin Rehabil 2000;14:5-13.
23. Yelnik AP, Colle FM, Bonan IV, Vicaut E. Treatment of shoulder pain in spastic hemiplegia by reducing spasticity of the subscapular muscle: a randomised, double blind, placebo controlled study of botulinum toxin A. J Neurol Neurosurg Psychiatry 2007;78:845-8.
24. Rosales RL, Chua-Yap AS. Evidence-based systematic review on the efficacy and safety of botulinum toxin-A therapy in poststroke spasticity. J Neural Transm 2008;115:617-23.
25. Burbaud P, Wiart L, Dubos JL, Gaujard E, Debelleix X, Joseph PA et al. A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry 1996;61:265-9.
26. Hyman N, Barnes M, Bhakta B, Cozens A, Bakheit M, Kreczy-Kleedorfer B et al. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry 2000;68:707-12.
27. Rousseaux M, Compere S, Launay MJ, Kozlowski O. Variability and predictability of functional efficacy of botulinum toxin injection in leg spastic muscles. J Neurol Sci 2005;232:51-7.
28. Yelnik A, Colle F, Bonan I, Bradai N. [Efficacy at six months of the botulinum toxin A in the post-stroke lower limb's muscular overactivity]. Ann Readapt Med Phys 2002;45:159-65.
29. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987;67:206-7.
30. Physicians RCo, Medicine BSoR, Physiotherapy CSo, Neurology AoCPIi. Spasticity in adults: management using botulinum toxin. National guidelines. London: RCP, 2009.
31. Kanovsky P, Slawek J, Denes Z, Platz T, Sassin I, Comes G et al. Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity. Clin Neuropharmacol 2009;32:259-65.
32. Barnes M, Schnitzler A, Medeiros L, Aguilar M, Lehnert-Batar A, Minnasch P. Efficacy and safety of NT 201 for upper limb spasticity of various etiologies - a randomized parallel-group study. Acta Neurol Scand.
33. Dressler D. Routine use of Xeomin in patients previously treated with Botox: long term results. Eur J Neurol 2009;16 Suppl 2:2-5.
34. Wissel J, Ward AB, Erztgaard P, Bensmail D, Hecht MJ, Lejeune TM et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med 2009;41:13-25.
35. Geenen C, Consky E, Ashby P. Localizing muscles for botulinum toxin treatment of focal hand dystonia. Can J Neurol Sci 1996;23:194-7.
36. O'Brien CF. Injection techniques for Botulinum toxin using electromyography and electrical stimulation. In: Mayer NH, Simpson DM, editors. Spasticity: Etiology, evaluation, management and the role of botulinum toxin. New York: we move; 2002 p. 131-3.
37. Patwa HS. Is needle electromyography safe in patients on anticoagulation or antiplatelet therapy? Nat Clin Pract Neurol 2009;5:78-9.
38. Mezaki T, Sakai R. Botulinum toxin and skin rash reaction. Mov Disord 2005;20:770.
39. Poulain B. [Botulinum neurotoxin]. Rev Neurol (Paris); 166:7-20.
40. A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group. Neurology 1994;44:S70-8.
41. Smith MB, Brar SP, Nelson LM, Franklin GM, Cobble ND. Baclofen effect on quadriceps strength in multiple sclerosis. Arch Phys Med Rehabil 1992;73:237-40.
42. Jerusalem F. [Double-blind study on the antispastic effect of beta-94-chlorphenyl)-gamma aminobutyric acid (CIBA) in multiple sclerosis]. Nervenarzt 1968;39:515-7.
43. Smith C, Birnbaum G, Carter JL, Greenstein J, Lublin FD. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group. Neurology 1994;44:S34-42;discussion S42-3.
44. Young RR, Emre M. Current issues in spasticity management. The Neurologist 1997;3:261-275.
45. Young RR, Delwaide PJ. Drug therapy: spasticity (second of two parts). N Engl J Med 1981;304:96-9.
46. Yang K, Wang D, Li YQ. Distribution and depression of the GABA(B) receptor in the spinal dorsal horn of adult rat. Brain Res Bull 2001;55:479-85.
47. Hill DR, Bowery NG. 3H-baclofen and 3H-GABA bind to bicuculline- insensitive GABA B sites in rat brain. Nature 1981;290:149-52.
48. Jamous A, Kennedy P, Psychol C, Grey N. Psychological and emotional effects of the use of oral baclofen: a preliminary study. Paraplegia 1994;32:349-53.
49. Terrence CF, Fromm GH. Complications of baclofen withdrawal. Arch Neurol 1981;38:588-9.
50. Hulme A, MacLennan WJ, Ritchie RT, John VA, Shotton PA. Baclofen in the elderly stroke patient its side-effects and pharmacokinetics. Eur J Clin Pharmacol 1985;29:467-9.
51. Terrence CF, Fromm GH, Roussan MS. Baclofen. Its effect on seizure frequency. Arch Neurol 1983;40:28-9.
52. Wagstaff AJ, Bryson HM. Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs 1997;53:435-52.
53. Davies J. Selective depression of synaptic transmission of spinal neurones in the cat by a new centrally acting muscle relaxant, 5-chloro-4-(2-imidazolin-2-yl-amino)-2, 1, 3-benzothiodazole (DS103-282). Br J Pharmacol 1982;76:473-81.
54. Palmeri A, Wiesendanger M. Concomitant depression of locus coeruleus neurons and of flexor reflexes by an alpha 2-adrenergic agonist in rats: a possible mechanism for an alpha 2-mediated muscle relaxation. Neuroscience 1990;34:177-87.
55. Gracies JM, Nance P, Elovic E, McGuire J, Simpson DM. Traditional pharmacologic treatments of spasticity - Part II Systemic treatments. In: Mayer NH, Simpson DM, eds. Spasticity: Etiology, Evaluation, Management and the Role of Botulinum Toxin. New York: WE MOVE, 2002:65-93.
56. Lakhan SE, Rowland M. Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review. BMC Neurol 2009;9:59.
57. Penn RD. Intrathecal baclofen for spasticity of spinal origin: seven years of experience. J Neurosurg 1992;77:236-40.
58. Ivanhoe CB, Tilton AH, Francisco GE. Intrathecal baclofen therapy for spastic hypertonia. Phys Med Rehabil Clin N Am 2001;12:923-38, viii-ix.
59. Zahavi A, Geertzen JH, Middel B, Staal M, Rietman JS. Long term effect (more than five years) of intrathecal baclofen on impairment, disability, and quality of life in patients with severe spasticity of spinal origin. J Neurol Neurosurg Psychiatry 2004;75:1553-7.
60. Azouvi P, Mane M, Thiebaut JB, Denys P, Remy-Neris O, Bussel B. Intrathecal baclofen administration for control of severe spinal spasticity: functional improvement and long-term followup. Arch Phys Med Rehabil 1996;77:35-9.
61. Ben Smail D, Peskine A, Roche N, Mailhan L, Thiebaut I, Bussel B. Intrathecal baclofen for treatment of spasticity of multiple sclerosis patients. Mult Scler 2006;12:101-3. (Pubitemid 43169244)
62. Bensmail D, Quera Salva MA, Roche N, Benyahia S, Bohic M, Denys P et al. Effect of intrathecal baclofen on sleep and respiratory function in patients with spasticity. Neurology 2006;67:1432-6. (Pubitemid 44632068)
63. Burns AS, Meythaler JM. Intrathecal baclofen in tetraplegia of spinal origin: efficacy for upper extremity hypertonia. Spinal Cord 2001;39:413-9.
64. Coffey JR, Cahill D, Steers W, , Park TS, Ordia J, Meythaler J et al. Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study. J Neurosurg 1993;78:226-32.
65. Dario A, Di Stefano MG, Grossi A, Casagrande F, Bono G. Longterm intrathecal Baclofen infusion in supraspinal spasticity of adulthood. Acta Neurol Scand 2002;105:83-7.
66. Denys P, Mane M, Azouvi P, Chartier-Kastler E, Thiebaut JB, Bussel B. Side effects of chronic intrathecal baclofen on erection and ejaculation in patients with spinal cord lesions. Arch Phys Med Rehabil 1998;79:494-6.
67. Guillaume D, Van Havenbergh A, Vloeberghs M, Vidal J, Roeste G. A clinical study of intrathecal baclofen using a programmable pump for intractable spasticity. Arch Phys Med Rehabil 2005;86:2165-71.
68. Hugenholtz H, Nelson RF, Dehoux E, Bickerton R. Intrathecal baclofen for intractable spinal spasticity - a double-blind crossover comparison with placebo in 6 patients. Can J Neurol Sci 1992;19:188-95.
69. Meythaler JM, Guin-Renfroe S, Brunner RC, Hadley MN. Intrathecal baclofen for spastic hypertonia from stroke. Stroke 2001;32:2099-109.
70. Middel B, Kuipers-Upmeijer H, Bouma J, Staal M, Oenema D, Postma T et al. Effect of intrathecal baclofen delivered by an implanted programmable pump on health related quality of life in patients with severe spasticity. J Neurol Neurosurg Psychiatry 1997;63:204-9.
71. Ochs GA, Tonn JC. Functional Outcome and Clinical Significance of Long-term Intrathecal Baclofen Therapy for Severe Spasticity. Neurorehab Neural Repair 1996;10:159-166.
72. Parke B, Penn RD, Savoy SM, Corcos D. Functional outcome after delivery of intrathecal baclofen. Arch Phys Med Rehabil 1989;70:30-2.
73. Patterson V, Watt M, Byrnes D, Crowe D, Lee A. Management of severe spasticity with intrathecal baclofen delivered by a manually operated pump. J Neurol Neurosurg Psychiatry 1994;57:582-5.
74. Penn RD, Kroin JS. Continuous intrathecal baclofen for severe spasticity. Lancet 1985;2:125-7.
75. Penn RD, Savoy SM, Corcos D, Latash M, Gottlieb G, Parke B et al. Intrathecal baclofen for severe spinal spasticity. N Engl J Med 1989;320:1517-21. (Pubitemid 19145803)
76. Remy-Neris O, Tiffreau V, Bouilland S, Bussel B. Intrathecal baclofen in subjects with spastic hemiplegia: assessment of the antispastic effect during gait. Arch Phys Med Rehabil 2003;84:643-50.
77. Stempien L, Tsai T. Intrathecal baclofen pump use for spasticity: a clinical survey. Am J Phys Med Rehabil 2000;79:536-41.
78. Van Schaeybroeck P, Nuttin B, Lagae L, Schrijvers E, Borghgraef C, Feys P. Intrathecal baclofen for intractable cerebral spasticity: a prospective placebo-controlled, double-blind study. Neurosurgery 2000;46:603-9;discussion 609-12.
79. Zierski J, Muller H, Dralle D, Wurdinger T. Implanted pump systems for treatment of spasticity. Acta Neurochir Suppl (Wien) 1988;43:94-9.
80. Gardner B, Jamous A, Teddy P, Bergstrom E, Wang D, Ravichandran G et al. Intrathecal baclofen - a multicentre clinical comparison of the Medtronics Programmable, Cordis Secor and Constant Infusion Infusaid drug delivery systems. Paraplegia 1995;33:551-4.
81. Romijn JA, van Lieshout JJ, Velis DN. Reversible coma due to intrathecal baclofen. Lancet 1986;2:696.
82. Reeves RK, Stolp-Smith KA, Christopherson MW. Hyperthermia, rhabdomyolysis, and disseminated intravascular coagulation associated with baclofen pump catheter failure. Arch Phys Med Rehabil 1998;79:353-6.
83. Samson-Fang L, Gooch J, Norlin C. Intrathecal baclofen withdrawal simulating neuroepileptic malignant syndrome in a child with cerebral palsy. Dev Med Child Neurol 2000;42:561-5.
84. Al-Khodairy AT, Vuagnat H, Uebelhart D. Symptoms of recurrent intrathecal baclofen withdrawal resulting from drug delivery failure: a case report. Am J Phys Med Rehabil 1999;78:272-7.
85. Heetla HW, Staal MJ, Kliphuis C, van Laar T. The incidence and management of tolerance in intrathecal baclofen therapy. Spinal Cord 2009;47:751-6.
86. Albright AL, Awaad Y, Muhonen M, Boydston WR, Gilmartin R, Krach LE et al. Performance and complications associated with the synchromed 10-ml infusion pump for intrathecal baclofen administration in children. J Neurosurg 2004;101:64-8.
87. Campbell WM, Ferrel A, McLaughlin JF, Grant GA, Loeser JD, Graubert C et al. Long-term safety and efficacy of continuous intrathecal baclofen. Dev Med Child Neurol 2002;44:660-5.
88. Viel EJ, Perennou D, Ripart J, Pelissier J, Eledjam JJ. Neurolytic blockade of the obturator nerve for intractable spasticity of adductor thigh muscles. Eur J Pain 2002;6:97-104.
89. Chua KS, Kong KH. Alcohol neurolysis of the sciatic nerve in the treatment of hemiplegic knee flexor spasticity: clinical outcomes. Arch Phys Med Rehabil 2000;81:1432-5.
90. Chua KS, Kong KH. Clinical and functional outcome after alcohol neurolysis of the tibial nerve for ankle-foot spasticity. Brain Inj 2001;15:733-9.
91. Jang SH, Ahn SH, Park SM, Kim SH, Lee KH, Lee ZI. Alcohol neurolysis of tibial nerve motor branches to the gastrocnemius muscle to treat ankle spasticity in patients with hemiplegic stroke. Arch Phys Med Rehabil 2004;85:506-8.
92. Keenan MA, Tomas ES, Stone L, Gersten LM. Percutaneous phenol block of the musculocutaneous nerve to control elbow flexor spasticity. J Hand Surg [Am] 1990;15:340-6.
93. Kirazli Y, On AY, Kismali B, Aksit R. Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke: a randomized, double-blind trial. Am J Phys Med Rehabil 1998;77:510-5.
94. Kong KH, Chua KS. Neurolysis of the musculocutaneous nerve with alcohol to treat poststroke elbow flexor spasticity. Arch Phys Med Rehabil 1999;80:1234-6.
95. Ofluoglu D, Esquenazi A, Hirai B. Temporospatial parameters of gait after obturator neurolysis in patients with spasticity. Am J Phys Med Rehabil 2003;82:832-6.